51 entries. Each one states what it is claimed to do, then what human evidence actually exists for that claim. Where the answer is “none,” it says none.
The first-generation daily GLP-1. Superseded on potency, but with long outcome data.
Not a peptide at all — and that is the point. The first oral small-molecule GLP-1, approved April 2026.
The original approved amylin analogue — the ancestor of today's amylin obesity drugs.
A prescription GLP-1 with a real FDA label and some of the largest outcome trials in medicine.
An approved melanocortin peptide — but only for specific genetic obesity syndromes.
An approved dual-receptor drug with the largest average weight loss of any approved agent.
An amylin analogue built to pair with semaglutide rather than replace it.
An oxyntomodulin-based dual agonist approved in China, unapproved in the US.
A triple agonist in late-stage trials with the largest phase 2 weight loss ever published.
A glucagon/GLP-1 dual agonist with unusually strong phase 2 liver data.
An EPO-derived peptide with actual randomised human neuropathy trials — and no approval.
The most rigorously tested 'leaky gut' peptide — and it failed its phase 3.
The best-supported cosmetic peptide — for skin, topically, at modest effect sizes.
A natural human antimicrobial peptide with a genuine small wound-healing trial behind it.
The real molecule behind the TB-500 story — and it has actually been in human trials.
The recovery peptide everyone researches first. Robust in animals, untested in humans.
The anti-inflammatory tail of α-MSH, studied mainly in mouse colitis and skin models.
A thymosin β4 fragment carrying the reputation of the full peptide's animal research.
Was an approved diagnostic and paediatric GH agent. Withdrawn commercially, now compounded.
The only GH-axis peptide with a real FDA approval — for one specific indication.
A GH fragment that was properly tested for obesity in humans — and did not work.
A GHRH analogue that reliably raises GH in humans — with no outcome trials behind it.
Approved in Japan purely as a pituitary diagnostic test — not as a therapy.
The original GHRP. Powerful appetite stimulation, no efficacy approvals anywhere.
The GHRP with the most interesting cardiac pharmacology and the least follow-through.
The 'clean' GH secretagogue — selective, well characterised pharmacologically, unproven clinically.
A muscle-specific IGF-1 splice variant. Real biology in rodents, nothing in humans.
A myostatin binder sold as an injectable, with a half-life that makes injection near-pointless.
A cell-culture research reagent sold as a physique drug. That is genuinely what it is.
An approved obstetric drug with an enormous, largely unsupported social-behaviour literature.
Genuinely large randomised trials, genuinely contested results, no FDA approval.
The only peptide the July 2026 FDA panel voted down — and the sleep data explains why.
An anxiolytic peptide registered in Russia, with the same evidence-access problem as Semax.
A Russian clinical drug with decades of domestic use and almost no Western trial data.
Extraordinary rodent synaptogenesis data, and not one human trial.
The one mitochondrial peptide that made it to approval — for a rare genetic cardiomyopathy.
The telomerase peptide. Extraordinary claims, Russian-only data, no Western replication.
A genuine mitochondrial-derived peptide with excellent mouse data and no human trials.
The first mitochondrial-derived peptide discovered. Entirely preclinical.
The most clinically legitimate immune peptide — approved widely, just not by the FDA.
One of the very few peptides FDA placed in Category 1 — with contested clinical results.
A Russian thymic extract with a long domestic record and no Western validation.
Melanotan I done properly: an approved implant for a rare light-sensitivity disease.
An approved libido drug — for one specific population, with a modest effect size.
A real reproductive hormone with genuine Imperial College trial data behind it.
The tanning peptide with real regulatory warnings and documented harm reports.
The 'topical Botox' peptide. Small cosmetic studies, small effects, and a delivery problem.
A real endogenous antioxidant with a large, poorly supported cosmetic industry around it.
One of the few cosmetic peptides with a genuinely independent controlled trial.
An extended Argireline analogue with even less independent evidence.